Literature DB >> 18182259

Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.

Kapil Khatri1, Amit K Goyal, Prem N Gupta, Neeraj Mishra, Suresh P Vyas.   

Abstract

This work investigates the preparation and in vivo efficacy of plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Chitosan pDNA nanoparticles were prepared using a complex coacervation process. Prepared nanoparticles were characterized for size, shape, surface charge, plasmid loading and ability of nanoparticles to protect DNA against nuclease digestion and for their transfection efficacy. Nasal administration of nanoparticles resulted in serum anti-HBsAg titre that was less compared to that elicited by naked DNA and alum adsorbed HBsAg, but the mice were seroprotective within 2 weeks and the immunoglobulin level was above the clinically protective level. However, intramuscular administration of naked DNA and alum adsorbed HBsAg did not elicit sIgA titre in mucosal secretions that was induced by nasal immunization with chitosan nanoparticles. Similarly, cellular responses (cytokine levels) were poor in case of alum adsorbed HBsAg. Chitosan nanoparticles thus produced humoral (both systemic and mucosal) and cellular immune responses upon nasal administration. The study signifies the potential of chitosan nanoparticles as DNA vaccine carrier and adjuvant for effective immunization through non-invasive nasal route.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18182259     DOI: 10.1016/j.ijpharm.2007.11.027

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  22 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

3.  In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery.

Authors:  Yen Cu; Carmen J Booth; W Mark Saltzman
Journal:  J Control Release       Date:  2011-07-08       Impact factor: 9.776

Review 4.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

Review 5.  Carbohydrate-based immune adjuvants.

Authors:  Nikolai Petrovsky; Peter D Cooper
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

6.  Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

Authors:  Dharmendra Raghuwanshi; Vivek Mishra; Dipankar Das; Kamaljit Kaur; Mavanur R Suresh
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

7.  Comparison on in vitro characterization of fucospheres and chitosan microspheres encapsulated plasmid DNA (pGM-CSF): formulation design and release characteristics.

Authors:  Ali Demir Sezer; Jülide Akbuğa
Journal:  AAPS PharmSciTech       Date:  2009-10-27       Impact factor: 3.246

Review 8.  Emerging Fabrication Strategies of Hydrogels and Its Applications.

Authors:  Fayaz Ali; Imran Khan; Jianmin Chen; Kalsoom Akhtar; Esraa M Bakhsh; Sher Bahadar Khan
Journal:  Gels       Date:  2022-03-24

Review 9.  Chitosans for delivery of nucleic acids.

Authors:  Michael D Buschmann; Abderrazzak Merzouki; Marc Lavertu; Marc Thibault; Myriam Jean; Vincent Darras
Journal:  Adv Drug Deliv Rev       Date:  2013-07-18       Impact factor: 15.470

10.  Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection.

Authors:  Ganzhu Feng; Qingtao Jiang; Mei Xia; Yanlai Lu; Wen Qiu; Dan Zhao; Liwei Lu; Guangyong Peng; Yingwei Wang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.